# VELIA (NCT02470585)

> Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02470585
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: AbbVie
- Conditions: Ovarian Cancer; Ovarian Neoplasm
- Interventions: Veliparib; Paclitaxel; Carboplatin; Placebo to Veliparib
- Enrollment: 1140
- Primary outcome: Progression-Free Survival (PFS) in the BRCA-deficient Population (Arm 3 vs Arm 1)
- Primary outcome: Progression-Free Survival (PFS) in the Homologous Recombination Deficiency Cohort (Arm 3 vs Arm 1)
- Primary outcome: Progression-Free Survival (PFS) in the Intention-to-treat Population (Arm 3 vs Arm 1)

## Commentary we found

- Podcasts: 4
- YouTube: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=velia-nct02470585